肝胆相照论坛

标题: 慢性乙型肝炎土拨鼠模型的最新药物开发 [打印本页]

作者: StephenW    时间: 2022-8-27 14:31     标题: 慢性乙型肝炎土拨鼠模型的最新药物开发

慢性乙型肝炎土拨鼠模型的最新药物开发
通过马纳萨苏雷什
[ORCID] 和斯蒂芬·梅内
* [兽人]
乔治敦大学医学中心,华盛顿特区 20057,美国
*
通讯作者。
学术编辑:Dohun Pyeon 和 Katerina Strati
病毒 2022, 14(8), 1711; https://doi.org/10.3390/v14081711
收到日期:2022 年 6 月 17 日 / 修订日期:2022 年 7 月 22 日 / 接受日期:2022 年 7 月 31 日 / 发布日期:2022 年 8 月 3 日
(这篇文章属于特刊 小DNA病毒研究的新前沿)
查看全文 下载 PDF 浏览图
引文导出
抽象的
乙型肝炎病毒 (HBV) 感染是造成全球肝炎负担增加的原因,估计有 2.96 亿人是携带者,并有患上慢性肝病和癌症的风险。虽然目前慢性乙型肝炎 (CHB) 的治疗选择,包括口服核苷(酸)类似物和全身性干扰素-α,被认为是次优的,但找到最终治愈这种病毒性疾病的途径是相当具有挑战性的。缺乏支持 HBV 感染和相关肝病进展的合适实验动物模型是抗病毒药物开发的主要障碍之一。四十多年来,东部土拨鼠用土拨鼠肝炎病毒的实验性感染已被用于研究 HBV 的免疫发病机制和开发针对 CHB 的新抗病毒疗法。这种动物模型有几个优点,有利于进行基础和转化 HBV 研究。以前的评论文章重点介绍了这种动物模型在 HBV 复制、发病机制和免疫反应方面的价值。在本文中,我们回顾了自 2014 年至今在 CHB 土拨鼠模型中直接作用的抗病毒药物、免疫调节剂、治疗性疫苗以及病毒进入、基因表达和抗原释放抑制剂的药物开发和临床前评估研究,并讨论了它们的意义用于患者的临床试验。查看全文
关键词:慢性乙型肝炎;抗病毒治疗;免疫疗法;土拨鼠;土拨鼠肝炎病毒
▼ 显示数字

图1
这是一篇根据知识共享署名许可分发的开放获取文章,只要正确引用了原始作品,它就允许在任何媒体中不受限制地使用、分发和复制。
作者: StephenW    时间: 2022-8-27 14:31

  Recent Drug Development in the Woodchuck Model of Chronic Hepatitis B
by Manasa Suresh
[ORCID] and Stephan Menne
* [ORCID]
Georgetown University Medical Center, Washington, DC 20057, USA
*
Author to whom correspondence should be addressed.
Academic Editors: Dohun Pyeon and Katerina Strati
Viruses 2022, 14(8), 1711; https://doi.org/10.3390/v14081711
Received: 17 June 2022 / Revised: 22 July 2022 / Accepted: 31 July 2022 / Published: 3 August 2022
(This article belongs to the Special Issue New Frontiers in Small DNA Virus Research)
View Full-Text Download PDF Browse Figures
Citation Export
Abstract
Infection with hepatitis B virus (HBV) is responsible for the increasing global hepatitis burden, with an estimated 296 million people being carriers and living with the risk of developing chronic liver disease and cancer. While the current treatment options for chronic hepatitis B (CHB), including oral nucleos(t)ide analogs and systemic interferon-alpha, are deemed suboptimal, the path to finding an ultimate cure for this viral disease is rather challenging. The lack of suitable laboratory animal models that support HBV infection and associated liver disease progression is one of the major hurdles in antiviral drug development. For more than four decades, experimental infection of the Eastern woodchuck with woodchuck hepatitis virus has been applied for studying the immunopathogenesis of HBV and developing new antiviral therapeutics against CHB. There are several advantages to this animal model that are beneficial for performing both basic and translational HBV research. Previous review articles have focused on the value of this animal model in regard to HBV replication, pathogenesis, and immune response. In this article, we review studies of drug development and preclinical evaluation of direct-acting antivirals, immunomodulators, therapeutic vaccines, and inhibitors of viral entry, gene expression, and antigen release in the woodchuck model of CHB since 2014 until today and discuss their significance for clinical trials in patients. View Full-Text
Keywords: chronic hepatitis B; antiviral therapy; immunotherapy; woodchuck; woodchuck hepatitis virus
▼ Show Figures

Figure 1
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

作者: StephenW    时间: 2022-8-27 14:32

https://www.mdpi.com/1999-4915/14/8/1711/pdf?version=1659531999
作者: newchinabok    时间: 2022-8-28 16:07

我看病的医院,病人四十岁以下的人几乎没有,都是四十以上到五十几岁的人。新药搞不出明堂,以后新药开发也没什么动力了
作者: 乙肝人1949    时间: 2022-8-28 17:03

讨厌。相当讨厌,净说实话
作者: tim889    时间: 2022-8-29 02:47

本帖最后由 tim889 于 2022-8-28 10:47 编辑
newchinabok 发表于 2022-8-28 00:07
我看病的医院,病人四十岁以下的人几乎没有,都是四十以上到五十几岁的人。新药搞不出明堂,以后新药开发也 ...

是的。就看这关键的10-15年




欢迎光临 肝胆相照论坛 (http://hbvhbv.info/forum/) Powered by Discuz! X1.5